Table 1 Baseline characteristics for the participants in the clinical trial.
Characteristic | Fluoxetine + Placebo | Fluoxetine + Serine | P value |
|---|---|---|---|
N | 20 | 20 | NA |
Sex | F | F | NA |
Age, years | 47.2 ± 5.3 | 48.4 ± 4.5 | 0.45 |
BMI, kg/m2 | 27.2 ± 3.8 | 27.8 ± 4.9 | 0.67 |
Weight change during the study (kg) | −0.54 ± 3.89 | 0.62 ± 4.12 | 0.37 |
Menopausal status, n (%) | |||
Postmenopausal | 12 (60%) | 13 (65%) | 1.00 |
Late perimenopausal | 8 (40%) | 7 (35%) | 1.00 |
Current calcium supplement user, n (%) | 5 (25%) | 4 (20%) | 1.00 |
Current vitamin D supplement user, n (%) | 5 (25%) | 5 (25%) | 1.00 |
Total lumbar spine BMD, g/cm2 | 0.94 ± 0.23 | 0.91 ± 0.17 | 0.64 |
Total hip BMD, g/cm2 | 0.94 ± 0.17 | 0.99 ± 0.22 | 0.43 |
Diagnosis | |||
MDD | 20 | 20 | N/A |
Montgomery–Åsberg depression rating scale | 28.6 ± 9.1 | 30.2 ± 7.8 | 0.55 |
Use of other medications that may modify fracture risk | |||
Proton-pump inhibitor, n (%) | 3 (15%) | 2 (10%) | 1.00 |
Thiazolidinediones, n (%) | 1 (5%) | 1 (5%) | 1.00 |
